Unlearn Closes $50 Million Series B Funding to Advance the Use of Its Machine Learning-Powered TwinRCTs™ in Clinical Trials
April 19, 2022
Led by Insight Partners, financing builds on the company’s momentum in working with leading biopharmaceutical companies to improve clinical trial efficiency.
Next-gen digital health innovation in clinical trials
December 8, 2020
The Rock Health team reflects on the evolution of digital in clinical trials, discuss the current state, and explore the opportunity to further transform drug discovery.
Unlearn.AI Announces Series A Extension with New Investment from Epic Ventures, Alumni Ventures Group, and Global Pharma Company Eisai
November 5, 2020
Eisai has joined the company’s world-class syndicate of investors as part of its Series A extension along with Epic Ventures and Alumni Ventures Group.
Funding Roundup: Company creating ‘digital twins’ for clinical trials raises $12M
April 24, 2020
Unlearn’s unique model has shown that it can provide realistic digital patient records to supplement actual control patients in Alzheimer’s Disease trials
Unlearn.AI Closes On $12M To Improve Clinical Trials
April 20, 2020
The Unlearn platform processes historical clinical trial datasets from thousands of patients to build the disease-specific machine-learning models used to create what is called “Digital Twins” and...
Unlearn Adds $12M for “Digital Twins” That Accelerate Clinical Trials
April 20, 2020
Unlearn has built disease-specific models that generate control patient data by using demographic information and observations of the same variables over time, such as common lab tests and...
Unlearn.AI nabs $12M to build “Digital Twins” to speed up and improve clinical trials
April 20, 2020
“Unlearn’s pioneering use of Digital Twins will limit the number of patients that need to go on placebo while also reducing overall trial enrollment time."
Unlearn.AI Closes $12M Series A to Advance the Use of Digital Twins in Clinical Trials
April 18, 2020
“This new financing marks an important milestone in our growth and will contribute to the significant progress we are making with regulators and with our commercial partners, who are already...
CTAD Lessons for 2020: More Phase 2 Trials, More Diversity
January 10, 2020
Smith and colleagues used 18 months of data on 1,909 patients from the Coalition Against Major Diseases (CAMD) AD database to develop an algorithm for generating digital twins.
AI, machine learning offer hope for speeding Alzheimer's development
January 3, 2020
Machine learning and artificial intelligence (AI) are already being actively used in drug discovery to evaluate potential binding of small-molecule drugs to proteins, but there's potential for the...
Digital Twin Advances Poised to Expand Clinical Trial Reach
November 25, 2019
Digital twins enable faster recruitment with higher powered, individualized trials [capable of generating] additional data from the same or fewer number of patients.
The FDA needs to set standards for using artificial intelligence in drug development
November 7, 2019
Clinical trials could be made more efficient by using artificial intelligence to incorporate other data sources, such as historical control arms or real-world data.
Broadening Role for External Control Arms in Clinical Trials
July 12, 2019
Unlearn.AI Inc. is going a step further, using data from historical trials and patient registries to build algorithms that simulate artificial patients.
Researcher use AI to predict Alzheimer's disease progression
February 2, 2019
“Understanding how to predict and manage differences between patients is the primary goal of precision medicine. Computational models of disease progression developed using machine learning...